Alexion Pharmaceuticals Inc. continues to reshape its top-level management after the company was hit by an internal investigation into its sales practices.
Alexion will start a search for a new Chief Financial Officer after current CFO Dave Anderson announced he will resign at the end of August. Anderson had joined the company in December after more than a decade as CFO at Honeywell International Inc. He had replaced Vikas Sinha, who resigned last year along with CEO David Hallal during the sales practices investigation.
Ludwig Hantson was named named Alexion’s chief executive in March.
The company has appointed Brian Goff as Chief Commercial Officer, effective June 1. Goff is a veteran biopharmaceutical executive with more than 25 years of experience at companies including Neurovance, Inc., Baxalta, Inc., Baxter, Novartis and Johnson & Johnson.
Earlier this year, Alexion found that some of its senior management staff had pressured employees to get customers to order its flagship drug Soliris earlier than needed to meet financial targets
Source: RTT News
Lars Fruergaard Jørgensen will step down from his role as CEO of Novo Nordisk. He will continue as CEO for a period to support a smooth transition to new leadership. A search for Lars Fruergaard Jørgensen’s successor is ongoing, and an announcement will be made in due course.
Bristol Myers Squibb has announced two major developments: the appointment of Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer, and a commitment to invest $40 billion in the United States over the next five years
On-dose authentication integrates security measures directly into the dosage form, providing fast product verification and traceability. When products are separated from their original packaging, taggants applied directly within the film coating provides a convenient way for companies to verify whether a product is authentic in markets around the world.
